Novavax Investor Relations

Positive results from the first co-administration study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine have been published in *The Lancet Respiratory Medicine*. The previously announced results demonstrate that vaccine efficacy and safety appeared to be preserved in those receiving both NVX-CoV2373, Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, and Seqirus' adjuvanted, trivalent seasonal influenza vaccine (aTIV) or a cell-based, quadrivalent seasonal influenza vaccine (QIVc), compared to those vaccinated with NVX-CoV2373 alone. The data confirmed no early safety concerns, with local and systemic reactogenicity largely absent or mild in all groups.

The paper, '*Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial,*' is available here.

While additional research is underway, these findings suggest that concomitant vaccination may be a viable immunization strategy and may help inform immunization policy on co-administration of COVID-19 and influenza vaccines.
